Aptose Biosciences (APTO) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
APTO-253 Remains in Focus for Aptose Biosciences (APTO); Roth Affirms at 'Buy'
November 11, 2015 2:11 PM ESTRoth Capital affirms Aptose Biosciences (Nasdaq: APTO) with a Buy rating and $20 price target following the company's Q3 report and update issued Tuesday night. Aptose reported Q3 EPS of ($0.27), hich was $0.06 better than the consensus estimate of ($0.33).
Analyst Joseph Pantginis commented,... More
